SCHEMBL30259281

SCHEMBL30259281

CCOc1ccn2cc(C3CCOCC3)nc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 5/20 0.46
ALDH1A1 P00352 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
KDM4E B2RXH2 3/20 0.40
HSD17B10 Q99714 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
HPGD P15428 2/20 0.40
MEN1 O00255 1/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
CASP1 P29466 1/20 0.40
STAT1 P42224 1/20 0.40
CASP7 P55210 1/20 0.40
KMT2A Q03164 1/20 0.40
ATM Q13315 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PSEN1 P49768 1/20 0.39
PSEN2 P49810 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29372575 0.91 PDE10A (0.45) IRAK4ALDH1A1SMN1; SMN2KDM4ENPC1
SCHEMBL22234883 0.77 IRAK4 (0.52) IRAK4ALDH1A1SMN1; SMN2KDM4EHSD17B10
SCHEMBL22234923 0.77 IRAK4 (0.52) IRAK4ALDH1A1SMN1; SMN2HSD17B10NPC1
SCHEMBL29373194 0.76 NPC1 (0.47) KDM4ENPC1RAB9APKMPDE10A
SCHEMBL29373916 0.74 PDE10A (0.40) IRAK4PDE10ASUV39H2
SCHEMBL30427342 0.74 KDM4E (0.43) ALDH1A1SMN1; SMN2KDM4EHSD17B10NPC1
SCHEMBL22234896 0.73 IRAK4 (0.51) IRAK4ALDH1A1SMN1; SMN2KDM4ENPC1
SCHEMBL30259279 0.72 PDE10A (0.42) IRAK4KDM4ENPC1RAB9ATP53
SCHEMBL22234965 0.69 IRAK4 (0.40) IRAK4SMN1; SMN2PSEN1PSEN2APH1B
SCHEMBL22235254 0.69 IRAK4 (0.38) IRAK4SMN1; SMN2PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230087118-A1 IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE BIOGEN MA INC. 2023-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230087118-A1 IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE IRAK4, IRAK2, IRAK1 IRAK4 1/4885ALDH1A1 1138/4885SMN1; SMN2 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.